Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma

Patients with severe eosinophilic asthma (SEA) suffer from frequent asthma exacerbations, where eosinophils are major effector cells in airway inflammation, and anti-interleukin (IL)-5 becomes an effective treatment modality to control eosinophilic inflammation of SEA. Fifteen patients with SEA who...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy Asthma Immunol Res
Main Authors: Jang, Jae-Hyuk, Woo, Seong-Dae, Lee, Youngsoo, Kim, Chang-Keun, Shin, Yoo Seob, Ye, Young-Min, Park, Hae-Sim
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7840863/
https://ncbi.nlm.nih.gov/pubmed/33474865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4168/aair.2021.13.2.330
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados